

DIN EN ISO 11615:2022-12 (E)

Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated medicinal product information (ISO 11615:2017 + Amd 1:2022) (includes Amendment :2022)

Contents		Page
	European foreword	5
	A1 European foreword to Amendment A1	6
	Foreword	7
	A1 Foreword to Amendment A1	8
	Introduction	9
1	Scope	11
2	Normative references	11
3	Terms, definitions and abbreviated terms	12
4	Message exchange format	23
5	Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications	24
6	Concepts required for the unique identification of Medicinal Products	24
	6.1 General considerations	24
	6.2 Authorised Medicinal Products	24
	6.3 Investigational Medicinal Products	25
	6.4 Concepts required for the unique identification of a Medicinal Product and the association with PhPID(s)	25
	6.5 Concepts required for the unique identification of Medicinal Products and the association with the marketing authorisation number	25
	6.6 Concepts required for the unique identification of Medicinal Products and the association with data carrier identifiers	26
7	Description of the information modelling principles and practices	27
	7.1 General considerations	27
	7.2 Conceptual overview diagrams	27
	7.3 High-level diagrams	28
	7.4 Detailed description diagrams	28
	7.4.1 General	28
	7.4.2 Relationships between classes	29
	7.4.3 Attributes of classes	30
	7.4.4 Generalised classes and patterns	30
	7.4.5 Translation and language	30
8	Identifying characteristics for authorised Medicinal Products	30
	8.1 Primary identifiers — General considerations	30
	8.2 Medicinal Product Identifier (MPID)	31
	8.2.1 General considerations	31
	8.2.2 MPID code segments	31
	8.3 Packaged Medicinal Product Identifier (PCID)	32
	8.3.1 General considerations	32
	8.3.2 Package description (PCID) code segment	33
	8.4 Medicinal Product Batch Identifier (BAID1)	33
	8.5 Medicinal Product Batch Identifier (BAID2)	33
9	Information for an authorised Medicinal Product	34
	9.1 Authorised Medicinal Product — Information overview	34

9.1.1	General.....	34
9.1.2	Medicinal Product.....	34
9.1.3	Medicinal Product name.....	34
9.1.4	Header.....	35
9.1.5	Manufacturer/Establishment (organisation).....	35
9.1.6	Marketing authorisation.....	35
9.1.7	Packaged Medicinal Product.....	35
9.1.8	Pharmaceutical product.....	35
9.1.9	Ingredient.....	35
9.1.10	Clinical particulars.....	35
9.2	Medicinal Product.....	35
9.2.1	General.....	35
9.2.2	Detailed description of Medicinal Product information.....	36
9.3	Marketing authorisation.....	42
9.3.1	General.....	42
9.3.2	Detailed description of marketing authorisation information.....	43
9.4	Organisation.....	48
9.4.1	General.....	48
9.4.2	Detailed description of organisation information.....	49
9.5	Manufacturer/Establishment (organisation).....	51
9.5.1	General.....	51
9.5.2	Detailed description of manufacturer/establishment (organisation) information.....	51
9.6	Packaged Medicinal Product, including manufactured item and device.....	52
9.6.1	General.....	52
9.6.2	Detailed description of Packaged Medicinal Product information.....	53
9.7	Ingredient, substance and strength.....	62
9.7.1	General.....	62
9.7.2	Detailed description of ingredients, substance and strength information.....	62
9.8	Pharmaceutical product and device.....	65
9.8.1	General.....	65
9.8.2	Detailed description of pharmaceutical product and device information.....	65
9.9	Clinical particulars.....	67
9.9.1	General.....	67
9.9.2	Detailed description for clinical particulars information.....	68
10	Identifying characteristics for Investigational Medicinal Products.....	72
10.1	General.....	72
10.2	Primary identifiers.....	72
10.2.1	General considerations.....	72
10.3	Investigational Medicinal Product Identifier (IMPID).....	73
10.3.1	General considerations.....	73
10.3.2	IMPID code segments.....	73
10.4	Investigational Medicinal Product Package Identifier (IPCID).....	74
10.4.1	General provisions.....	74
10.4.2	Package description code segment.....	74
10.5	Investigational Medicinal Product Batch Identifier (BAID1).....	75
10.6	Investigational Medicinal Product Batch Identifier (BAID2).....	75
11	Information for an Investigational Medicinal Product.....	75
11.1	General.....	75
11.2	Conceptual overview of the information for an Investigational Medicinal Product.....	75
11.2.1	General.....	75
11.2.2	Investigational Medicinal Product.....	76
11.2.3	Investigational Medicinal Product name.....	76
11.2.4	Header.....	76
11.2.5	Manufacturer/Establishment (organisation).....	76
11.2.6	Clinical trial authorisation.....	77
11.2.7	Investigational Packaged Medicinal Product.....	77
11.2.8	Pharmaceutical product.....	77
11.2.9	Ingredient.....	77
11.2.10	Clinical particulars.....	77
11.3	Investigational Medicinal Product.....	77
11.3.1	General.....	77
11.3.2	Detailed description of Investigational Medicinal Product information.....	77

11.4	Clinical trial authorisation	80
11.4.1	General.....	80
11.4.2	Detailed description of clinical trial authorisation information.....	80
11.5	Manufacturer/Establishment (organisation).....	82
11.6	Investigational Packaged Medicinal Product.....	82
11.7	Pharmaceutical product.....	82
11.7.1	General.....	82
11.7.2	Pharmaceutical product.....	83
11.7.3	Dosing and route of administration	83
11.8	Ingredient.....	83
11.9	Clinical particulars.....	84
11.10	PhPID sets	84
11.11	Device nomenclature.....	84
11.12	Device batch identifier.....	84
11.13	Physical characteristics	84
11.14	Other characteristics.....	84
Annex A (normative) Full model — Authorised Medicinal Products detailed diagram.....		85
Annex B (normative) Full model — Investigational Medicinal Products detailed diagram		86
[A₁] Annex C (informative) Class name and attribute translations and synonyms for the identification of medicinal products (IDMP) [A₁]		87
Bibliography		88